Related Experiment Video
Updated: Apr 18, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Targeting LUNX inhibits non-small cell lung cancer growth and metastasis
Xiaohu Zheng1, Min Cheng2, Binqing Fu1
1Institute of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China. Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui, China.
Abstract:
There remains a great need for effective therapies for lung cancer, the majority of which are non-small cell lung cancers (NSCLC). Here, we report the identification of a novel candidate therapeutic target, LUNX, as a molecule overexpressed in primary NSCLC and lymph node metastases that is associated with reduced postoperative survival. Functional studies demonstrated that LUNX overexpression promoted lung cancer cell migration and proliferation by interactions with the chaperone protein 14-3-3. Conversely, LUNX silencing disrupted primary tumor growth, local invasion, and metastatic colonization. The finding that LUNX was expressed on cell membranes prompted us to generate and characterize LUNX antibodies as a candidate therapeutic. Anti-LUNX could downregulate LUNX and reduce lung cancer cell proliferation and migration in vitro. Administered in vivo to mice bearing lung cancer xenografts, anti-LUNX could slow tumor growth and metastasis and improve mouse survival. Together, our work provides a preclinical proof of concept for LUNX as a novel candidate target for immunotherapy in lung cancer.
Insights
Researchers identified LUNX as a novel therapeutic target for non-small cell lung cancer (NSCLC). Targeting LUNX with antibodies shows promise in slowing tumor growth and metastasis, offering a new immunotherapy approach for lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Non-small cell lung cancer (NSCLC) remains a significant unmet medical need, necessitating novel therapeutic strategies.
- Current treatments for NSCLC have limitations, highlighting the importance of identifying new molecular targets.
- Understanding the molecular mechanisms driving NSCLC progression is crucial for developing effective therapies.
Purpose of the Study:
- To identify and characterize novel therapeutic targets for non-small cell lung cancer (NSCLC).
- To investigate the role of the LUNX molecule in NSCLC progression and metastasis.
- To evaluate the therapeutic potential of anti-LUNX antibodies as an immunotherapy for NSCLC.
Main Methods:
- Identification of LUNX as an overexpressed molecule in primary NSCLC and lymph node metastases.
- Functional studies involving LUNX overexpression and silencing to assess its impact on cancer cell behavior.
- Generation and in vitro/in vivo characterization of anti-LUNX antibodies for therapeutic evaluation.
Main Results:
- LUNX overexpression was associated with reduced postoperative survival in NSCLC patients.
- LUNX promotes lung cancer cell migration and proliferation via interaction with 14-3-3 chaperone protein.
- LUNX silencing inhibited tumor growth, invasion, and metastasis; anti-LUNX antibodies demonstrated therapeutic efficacy in preclinical models.
Conclusions:
- LUNX is a promising novel therapeutic target for NSCLC, implicated in tumor progression and metastasis.
- Targeting LUNX with antibodies offers a potential new immunotherapy strategy for NSCLC.
- This study provides preclinical proof of concept for LUNX-targeted therapy in lung cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39lncRNA - Long Non-coding RNAs